Antiviral agents encompass a diverse range of pharmaceutical weapons in the ongoing battle against viral infections. Nucleoside analogs, exemplified by acyclovir and tenofovir, disrupt the viral life cycle by interfering with DNA or RNA synthesis, impeding the replication of viruses like herpes and HIV. Protease inhibitors, including ritonavir and lopinavir, play a crucial role in managing retroviruses like HIV by inhibiting the maturation of viral proteins. Neuraminidase inhibitors, such as oseltamivir, prove instrumental in treating influenza by preventing the release of new virus particles. Immunomodulators, like interferons, bolster the host's immune response, aiding in the identification and elimination of virus-infected cells. Entry inhibitors, like maraviroc, block the initial stages of viral infection by preventing the virus from entering host cells. Additionally, the cutting-edge RNA interference (RNAi)-based therapies target viral genes, utilizing the cell's natural defense mechanisms to silence specific viral genetic material, presenting a promising avenue for innovative antiviral interventions.
Title : Extensively drug-resistant bacterial infections: Confronting a global crisis with urgent solutions in prevention, surveillance, and treatment
Yazdan Mirzanejad, University of British Columbia, Canada
Title : Pathogen-derived noncanonical epitopes: Are they valuable targets for novel vaccinations and shall we be concerned about autoimmune responses?
Michele Mishto, Francis Crick Institute, United Kingdom
Title : Bioterrorism through the ages: Historical perspective, emerging threats, and medical countermeasures
Claudia Ferreira, Sorbonne University, France
Title : A rare case of meningitis and septicemia due to Streptococcus acidominimus
Percival C Dilla, Region II Trauma and Medical Center, Philippines
Title : Measles vaccination coverage indicators in 2023 and advance towards measles elimination and eradication by 2030
Pedro Plans Rubio, College of Physicians of Barcelona, Spain
Title : Association between cardiometabolic risk factors and COVID-19 severity in patients of a rural tertiary hospital
Percival C Dilla, Region II Trauma and Medical Center, Philippines